

L10 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2005:666528 CAPLUS Full-text

DN 143:221830

TI Novel 8-Substituted Dipyrindodiazepinone Inhibitors with a Broad-Spectrum of Activity against HIV-1 Strains Resistant to Non-nucleoside Reverse Transcriptase Inhibitors

AU O'Meara, Jeff A.; Yoakim, Christiane; Bonneau, Pierre R.; Boes, Michael; Cordingley, Michael G.; Deziel, Robert; Doyon, Louise; Duan, Jianmin; Garneau, Michel; Guse, Ingrid; Landry, Serge; Malenfant, Eric; Naud, Julie; Ogilvie, William W.; Thavonekham, Bounkham; Simoneau, Bruno

CS Boehringer Ingelheim (Canada) Ltd., Laval, QC, H7S 2G5, Can.

SO Journal of Medicinal Chemistry (2005), 48(17), 5580-5588


CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

GI




AB A series of novel 8-substituted dipyrindodiazepinone-based inhibitors were investigated for their antiviral activity against wild type human immunodeficiency virus (HIV-1) and the clin. prevalent K103N/Y181C mutant virus. Our efforts have resulted in a series of benzoic acid analogs that are potent inhibitors of HIV-1 replication against a panel of HIV-1 strains resistant to nonnucleoside reverse transcriptase inhibitors (NNRTIs). Furthermore, the combination of good antiviral potency, a broad spectrum of activity, and an excellent pharmacokinetic profile provides strong justification for the further development of compound (I) as a potential treatment for wild type and NNRTI-resistant HIV-1 infection.

IT 497066-93-0P 497068-02-7P 497068-15-2P
862889-12-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (novel 8-substituted dipyrindodiazepinone inhibitors with a broad-spectrum of activity against HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitors)


RN 497066-93-0 CAPLUS

CN 1-Naphthalenecarboxylic acid, 4-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 497068-02-7 CAPLUS

CN 1-Naphthalenecarboxylic acid, 5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 497068-15-2 CAPLUS

CN 2-Naphthalenecarboxylic acid, 6-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 862889-12-1 CAPLUS

CN 1-Naphthalenecarboxylic acid, 6-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]- (9CI) (CA INDEX NAME)



RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:451667 CAPLUS Full-text

DN 141:23559

TI Preparation of 5,11-dihydro-8-(2-hydroxyethyl)-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one derivatives as non-nucleoside reverse transcriptase inhibitors

IN Yoakim, Christiane; Malenfant, Eric; Thavonekham, Bounkham; Ogilvie, William; Deziel, Robert

PA Boehringer Ingelheim (Canada) Ltd., Can.

SO U.S. Pat. Appl. Publ., 27 pp.


CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004106791	A1	20040603	US 2003-662856	20030915
	CA 2495721	AA	20041007	CA 2003-2495721	20030915
	WO 2004085437	A1	20041007	WO 2003-CA1409	20030915
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
	EP 1554276	A1	20050720	EP 2003-816107	20030915
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK	
PRAI	US 2002-411785P	P	20020919		
	WO 2003-CA1409	W	20030915		
OS	MARPAT 141:23559				
GI					



AB The title compds. represented by formula (I) [wherein R1 = H, halogen, C1-4 alkyl, C1-4 alkoxy, haloalkyl; R2, R3 = H, C1-4 alkyl; R4 = C1-4 alkyl, C1-4 alkyl-C3-7 cycloalkyl, C3-7 cycloalkyl; Q = a fused phenyl-5 or 6-membered saturated heterocycle having one to two heteroatoms selected from O and N, said Q being optionally substituted with hydroxy, or C1-4 alkyl which in turn maybe optionally substituted with pyridinyl-N-oxide or CO2R (wherein R = H, C1-4 alkyl)] or salts thereof are prepared These compds. have inhibitory activity against wild type HIV and single and double mutants strains of HIV. Thus, Mitsunobu reaction of 2,3-Dihydro-1H-isoindole with 5,11-Dihydro-11-ethyl-8-(2-hydroxyethyl)-5-methyl-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one using DEAD and Ph3P in THF at room temperature for 16 h gave I (R1 = R2 = H, R3 = Me, R4 = Et, Q = 2,3-dihydro-1-oxo-1H-isoindol-4-yl) which showed IC50 of <10 μ M against RNA-dependent DNA polymerase of HIV-1 RT.


IT 697800-74-1P 697800-75-2P 697800-76-3P
697800-77-4P 697800-78-5P 697800-79-6P
697800-80-9P 697800-82-1P 697800-85-4P

697800-86-5P 697800-87-6P 697800-90-1P
 697800-91-2P 697800-94-5P 697800-95-6P
 697800-96-7P 697800-98-9P 697801-01-7P
 697801-04-0P 697801-05-1P 697801-09-5P
 697801-14-2P 697801-17-5P 697801-20-0P
 697801-25-5P 697801-27-7P 697801-31-3P
 697801-33-5P 697801-35-7P 697801-36-8P
 697801-38-0P 697801-40-4P 697801-64-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of 5,11-dihydro-8-(2-hydroxyethyl)-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one derivs. as non-nucleoside reverse transcriptase inhibitors and HIV inhibitors)


RN 697800-74-1 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[(2,3-dihydro-1-oxo-1H-isoindol-4-yl)oxy]ethyl]-11-ethyl-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 697800-75-2 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[(2,3-dihydro-1-oxo-1H-isoindol-4-yl)oxy]ethyl]-11-ethyl-5,11-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 697800-76-3 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[(2,3-dihydro-2-hydroxy-1-oxo-1H-isoindol-4-yl)oxy]ethyl]-11-ethyl-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 697800-77-4 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[[2,3-dihydro-1-oxo-2-(phenylmethyl)-1H-indol-4-yl]oxy]ethyl]-11-ethyl-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 697800-78-5 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[(2,3-dihydro-2-oxo-1H-indol-4-yl)oxy]ethyl]-11-ethyl-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 697800-79-6 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[(2,3-dihydro-1,3-dimethyl-2-oxo-1H-indol-4-yl)oxy]ethyl]-11-ethyl-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 697800-80-9 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-ethyl-5,11-dihydro-5-methyl-8-[2-[(1,2,3,4-tetrahydro-1-oxo-5-isoquinolinyl)oxy]ethyl]- (9CI)
(CA INDEX NAME)




RN 697800-82-1 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-ethyl-5,11-dihydro-4-methyl-8-[2-[(1,2,3,4-tetrahydro-1-oxo-5-isoquinolinyl)oxy]ethyl]- (9CI)
(CA INDEX NAME)




RN 697800-85-4 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-ethyl-5,11-dihydro-5-methyl-8-[2-[(1,2,3,4-tetrahydro-2-oxo-5-quinazolinyl)oxy]ethyl]- (9CI)
(CA INDEX NAME)




RN 697800-86-5 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-ethyl-5,11-dihydro-4-methyl-8-[2-[(1,2,3,4-tetrahydro-2-oxo-5-quinazolinyl)oxy]ethyl]- (9CI)
(CA INDEX NAME)




RN 697800-87-6 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-ethyl-5,11-dihydro-5-methyl-8-[2-[(1,2,3,4-tetrahydro-1,3-dimethyl-2-oxo-5-quinazolinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 697800-90-1 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-ethyl-5,11-dihydro-5-methyl-8-[2-[(1,2,3,4-tetrahydro-1-methyl-2-oxo-5-quinazolinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 697800-91-2 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl-8-[2-[(1,2,3,4-tetrahydro-2-oxo-5-quinazolinyl)oxy]ethyl]- (9CI)
(CA INDEX NAME)




RN 697800-94-5 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-ethyl-5,11-dihydro-4-methyl-8-[2-[(1,2,3,4-tetrahydro-1,3-dimethyl-2-oxo-5-quinazolinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 697800-95-6 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-ethyl-5,11-dihydro-4-methyl-8-[2-[(1,2,3,4-tetrahydro-1-methyl-2-oxo-5-quinazolinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 697800-96-7 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 5,11-diethyl-5,11-dihydro-8-[2-[(1,2,3,4-tetrahydro-2-oxo-5-quinazolinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 697800-98-9 CAPLUS

CN 1(2H)-Quinazolineacetic acid, 5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-3,4-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 697801-01-7 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-ethyl-5,11-dihydro-5-methyl-8-[2-[(1,2,3,4-tetrahydro-1-methyl-2-oxo-6-quinazolinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 697801-04-0 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-ethyl-5,11-dihydro-5-methyl-8-[2-[(1,2,3,4-tetrahydro-1,3-dimethyl-2-oxo-6-quinazolinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 697801-05-1 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-ethyl-5,11-dihydro-5-methyl-8-[2-[(1,2,3,4-tetrahydro-2-oxo-6-quinazolinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 697801-09-5 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)oxy]ethyl]-11-ethyl-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 697801-14-2 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-ethyl-5,11-dihydro-5-methyl-8-[2-[(1,2,3,4-tetrahydro-3-oxo-8-isoquinolinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 697801-17-5 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[(3,4-dihydro-2-oxo-2H-1,3-benzoxazin-5-yl)oxy]ethyl]-11-ethyl-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 697801-20-0 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[(1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-5-yl)oxy]ethyl]-11-ethyl-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 697801-25-5 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[(1,4-dihydro-2-oxo-2H-3,1-benzoxazin-5-yl)oxy]ethyl]-11-ethyl-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 697801-27-7 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[(1,4-dihydro-2-oxo-2H-3,1-benzoxazin-5-yl)oxy]ethyl]-11-ethyl-5,11-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 697801-31-3 CAPLUS

CN 2H-3,1-Benzoxazine-1(4H)-acetic acid, 5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-2-oxo- (9CI) (CA INDEX NAME)




RN 697801-33-5 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[[2-(1,1-dimethylethyl)-2,3-dihydro-3-oxo-1,2-benzisoxazol-5-yl]oxy]ethyl]-11-ethyl-2-fluoro-5,11-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 697801-35-7 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[(2,3-dihydro-2-methyl-3-oxo-1,2-benzisoxazol-5-yl)oxy]ethyl]-11-ethyl-2-fluoro-5,11-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 697801-36-8 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[(2,3-dihydro-1,3-dimethyl-2-oxo-1H-benzimidazol-4-yl)oxy]ethyl]-11-ethyl-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 697801-38-0 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[(2,3-dihydro-3-methyl-2-oxo-1H-benzimidazol-4-yl)oxy]ethyl]-11-ethyl-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 697801-40-4 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[(1,4-dihydro-2-oxo-2H-3,1-benzoxazin-6-yl)oxy]ethyl]-11-ethyl-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 697801-64-2 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[(2,3-dihydro-1-methyl-2-oxo-1H-indol-4-yl)oxy]ethyl]-11-ethyl-5,11-dihydro-5-methyl- (9CI) (CA . INDEX NAME)



L10 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2003:117825 CAPLUS Full-text
 DN 138:170259
 TI Preparation of dipyridodiazepinones as reverse transcriptase inhibitors
 IN Ogilvie, William W.; Deziel, Robert; O'Meara, Jeffrey; Simoneau, Bruno
 PA Boehringer Ingelheim (Canada) Ltd., Can.
 SO PCT Int. Appl., 71 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003011862	A1	20030213	WO 2002-CA1161	20020726
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003171363	A1	20030911	US 2002-205094	20020725
	US 6673791	B2	20040106		
	CA 2450868	AA	20030213	CA 2002-2450868	20020726
	EP 1414820	A1	20040506	EP 2002-750729	20020726
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2004537568	T2	20041216	JP 2003-517054	20020726
PRAI	US 2001-308710P	P	20010730		
	WO 2002-CA1161	W	20020726		
OS	MARPAT 138:170259				
GI					



AB Title compds. [I; R2 = H, halo, NHNH2, alkyl, alkoxy, haloalkyl; R4 = H, Me; R5 = H, alkyl; R11 = alkyl, alkylcycloalkyl, cycloalkyl; Q = (substituted) naphthyl, fused phenylcycloalkyl, fused phenylheterocyclyl having 1-2 O, N, S], were prepared Thus, diisopropyl azodicarboxylate in THF was added dropwise to a mixture of 5,11-dihydro-11-ethyl-2-fluoro-5-methyl-8-(2-hydroxyethyl)-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, Ph3P, and 4-formyl-1-naphthol followed by stirring for 1 h to give 56% formyl-naphthyl ether derivative, which was stirred with AgNO3 and NaOH in EtOH/THF to give 62% title compound I (Q = 4-carboxynaphthyl-1-yl; R2 = F; R4 = H; R5 = Me; R11 = Et) (II). II showed IC50<100 nM against wild type HIV-1 reverse transcriptase.

IT 497066-93-0P 497066-95-2P 497066-99-6P
 497067-03-5P 497067-06-8P 497067-08-0P
 497067-11-5P 497067-12-6P 497067-15-9P
 497067-19-3P 497067-23-9P 497067-27-3P
 497067-30-8P 497067-32-0P 497067-36-4P
 497067-38-6P 497067-44-4P 497067-46-6P


497067-49-9P 497067-51-3P 497067-53-5P
 497067-56-8P 497067-59-1P 497067-62-6P
 497067-64-8P 497067-66-0P 497067-68-2P
 497067-69-3P 497067-70-6P 497067-71-7P
 497067-72-8P 497067-73-9P 497067-74-0P
 497067-75-1P 497067-77-3P 497067-78-4P
 497067-79-5P 497067-80-8P 497067-81-9P
 497067-82-0P 497067-83-1P 497067-84-2P
 497067-85-3P 497067-86-4P 497067-87-5P
 497067-88-6P 497067-89-7P 497067-90-0P
 497067-91-1P 497067-92-2P 497067-93-3P
 497067-94-4P 497067-95-5P 497067-96-6P
 497067-97-7P 497067-98-8P 497067-99-9P
 497068-00-5P 497068-01-6P 497068-02-7P
 497068-03-8P 497068-04-9P 497068-05-0P
 497068-06-1P 497068-07-2P 497068-08-3P
 497068-09-4P 497068-10-7P 497068-11-8P
 497068-12-9P 497068-13-0P 497068-14-1P
 497068-15-2P 497068-16-3P 497068-17-4P
 497068-18-5P 497068-19-6P 497068-20-9P
 497068-21-0P 497068-22-1P 497068-23-2P
 497068-24-3P 497068-25-4P 497068-26-5P
 497068-27-6P 497068-28-7P 497068-29-8P
 497068-30-1P 497068-31-2P 497068-32-3P
 497068-33-4P 497068-34-5P 497068-35-6P
 497068-36-7P 497068-37-8P 497068-38-9P
 497068-39-0P 497068-40-3P 497068-41-4P
 497068-90-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of dipyridodiazepinones as reverse transcriptase inhibitors)


RN 497066-93-0 CAPLUS

CN 1-Naphthalenecarboxylic acid, 4-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-
 5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]- (9CI) (CA INDEX
 NAME)




RN 497066-95-2 CAPLUS

CN 1-Naphthalenecarboxylic acid, 4-[2-(11-ethyl-6,11-dihydro-2,5-dimethyl-6-
 oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]- (9CI) (CA INDEX
 NAME)




RN 497066-99-6 CAPLUS

CN 1-Naphthalenecarboxylic acid, 4-[2-(11-ethyl-2-fluoro-6,11-dihydro-4-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]- (9CI)
(CA INDEX NAME)




RN 497067-03-5 CAPLUS

CN 1-Naphthalenecarboxylic acid, 4-[2-(11-ethyl-6,11-dihydro-4-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 497067-06-8 CAPLUS

CN 1-Naphthalenecarboxylic acid, 4-[2-(11-ethyl-2-fluoro-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]- (9CI)
(CA INDEX NAME)




RN 497067-08-0 CAPLUS

CN 1-Naphthalenecarboxylic acid, 4-[2-(2-chloro-11-ethyl-6,11-dihydro-4-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]- (9CI)
(CA INDEX NAME)




RN 497067-11-5 CAPLUS

CN 1-Naphthaleneacetic acid, 4-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 497067-12-6 CAPLUS

CN 1-Naphthaleneacetic acid, 4-[2-(11-ethyl-2-fluoro-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 497067-15-9 CAPLUS

CN 1-Naphthaleneacetic acid, 4-[2-(2-chloro-11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 497067-19-3 CAPLUS

CN 1-Naphthaleneacetic acid, 4-[2-(11-ethyl-6,11-dihydro-2,5-dimethyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 497067-23-9 CAPLUS

CN 1-Naphthaleneacetic acid, 4-[2-(2-chloro-11-ethyl-6,11-dihydro-4-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 497067-27-3 CAPLUS

CN 1-Naphthaleneacetic acid, 4-[2-(11-ethyl-6,11-dihydro-4-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 497067-30-8 CAPLUS

CN 1-Naphthaleneacetic acid, 4-[2-(11-ethyl-2-fluoro-6,11-dihydro-4-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 497067-32-0 CAPLUS

CN 1-Naphthaleneacetic acid, 4-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-, hydrazide (9CI) (CA INDEX NAME)




RN 497067-36-4 CAPLUS

CN 1-Naphthaleneacetic acid, 4-[2-(2-chloro-11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-, hydrazide (9CI)
(CA INDEX NAME)




RN 497067-38-6 CAPLUS

CN 1-Naphthaleneacetic acid, 4-[2-(11-ethyl-2-hydrazino-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-, hydrazide
(9CI) (CA INDEX NAME)




RN 497067-44-4 CAPLUS

CN 1-Naphthaleneacetamide, 4-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-(9CI) (CA INDEX NAME)




RN 497067-46-6 CAPLUS

CN 1-Naphthaleneacetamide, 4-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 497067-49-9 CAPLUS

CN 1-Naphthaleneacetic acid, 4-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-α-methyl- (9CI)
(CA INDEX NAME)




RN 497067-51-3 CAPLUS

CN 1-Naphthalenepropanoic acid, 4-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 497067-53-5 CAPLUS

CN 1-Naphthalenepropanoic acid, 4-[2-(2-chloro-11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 497067-56-8 CAPLUS

CN 1-Naphthalenepropanoic acid, 4-[2-(11-ethyl-2-fluoro-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 497067-59-1 CAPLUS

CN 1-Naphthalenepropanoic acid, 4-[2-(11-ethyl-6,11-dihydro-4-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 497067-62-6 CAPLUS

CN 1-Naphthalenepropanoic acid, 4-[2-(2-chloro-11-ethyl-6,11-dihydro-4-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 497067-64-8 CAPLUS

CN 1-Naphthalenepropanoic acid, 4-[2-(11-ethyl-6,11-dihydro-2,5-dimethyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 497067-66-0 CAPLUS

CN 1-Naphthalenepropanoic acid, 4-[2-(11-ethyl-2-fluoro-6,11-dihydro-4-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 497067-68-2 CAPLUS

CN 2-Propenoic acid, 3-[4-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-1-naphthalenyl]- (9CI)
(CA INDEX NAME)




RN 497067-69-3 CAPLUS

CN 2-Propenoic acid, 3-[4-[2-(2-chloro-11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-1-naphthalenyl]- (9CI)
(CA INDEX NAME)




RN 497067-70-6 CAPLUS

CN 2-Propenoic acid, 3-[4-[2-(2-chloro-11-ethyl-6,11-dihydro-4-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-1-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 497067-71-7 CAPLUS

CN 2-Propenoic acid, 3-[4-[2-(11-ethyl-6,11-dihydro-4-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-1-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 497067-72-8 CAPLUS

CN 2-Propenoic acid, 3-[4-[2-(11-ethyl-2-fluoro-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-1-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 497067-73-9 CAPLUS

CN 2-Propenoic acid, 3-[4-[2-(11-ethyl-6,11-dihydro-2,5-dimethyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-1-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 497067-74-0 CAPLUS

CN 2-Propenoic acid, 3-[4-[2-(11-ethyl-2-fluoro-6,11-dihydro-4-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-1-naphthalenyl]-(9CI) (CA INDEX NAME)




RN 497067-75-1 CAPLUS

CN 2-Propenoic acid, 3-[4-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-1-naphthalenyl]-2-methyl-(9CI) (CA INDEX NAME)




RN 497067-77-3 CAPLUS

CN 2-Propenoic acid, 3-[4-[2-(2-chloro-11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-1-naphthalenyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 497067-78-4 CAPLUS

CN 2-Propenoic acid, 3-[4-[2-(11-ethyl-2-fluoro-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-1-naphthalenyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 497067-79-5 CAPLUS

CN 2-Propenoic acid, 3-[4-[2-(11-ethyl-6,11-dihydro-2,5-dimethyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-1-naphthalenyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 497067-80-8 CAPLUS

CN 2-Propenoic acid, 3-[4-[2-(11-ethyl-6,11-dihydro-4-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-1-naphthalenyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 497067-81-9 CAPLUS

CN 2-Propenoic acid, 3-[4-[2-(2-chloro-11-ethyl-6,11-dihydro-4-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-1-naphthalenyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 497067-82-0 CAPLUS

CN 2-Propenoic acid, 3-[4-[2-(11-ethyl-2-fluoro-6,11-dihydro-4-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-1-naphthalenyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 497067-83-1 CAPLUS

CN 1-Naphthalenepropanoic acid, 4-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-α-methyl- (9CI)
(CA INDEX NAME)




RN 497067-84-2 CAPLUS

CN 1-Naphthalenepropanoic acid, 4-[2-(11-ethyl-2-fluoro-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-α-methyl- (9CI) (CA INDEX NAME)




RN 497067-85-3 CAPLUS

CN 1-Naphthalenepropanoic acid, 4-[2-(2-chloro-11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-α-methyl- (9CI) (CA INDEX NAME)




RN 497067-86-4 CAPLUS

CN 1-Naphthalenepropanoic acid, 4-[2-(11-ethyl-6,11-dihydro-2,5-dimethyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-α-methyl- (9CI) (CA INDEX NAME)




RN 497067-87-5 CAPLUS

CN 1-Naphthalenepropanoic acid, 4-[2-(11-ethyl-6,11-dihydro-4-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-α-methyl- (9CI)
(CA INDEX NAME)




RN 497067-88-6 CAPLUS

CN 1-Naphthalenepropanoic acid, 4-[2-(2-chloro-11-ethyl-6,11-dihydro-4-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-α-methyl- (9CI) (CA INDEX NAME)




RN 497067-89-7 CAPLUS

CN 2-Butenoic acid, 3-[4-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-1-naphthalenyl]- (9CI)
(CA INDEX NAME)




RN 497067-90-0 CAPLUS

CN 1-Naphthalenepropanoic acid, 4-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-β-methylene- (9CI)
(CA INDEX NAME)




RN 497067-91-1 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[4-[2-(11-ethyl-2-fluoro-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-1-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 497067-92-2 CAPLUS

CN 1-Naphthalenepropanoic acid, 4-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-β-methyl- (9CI) (CA INDEX NAME)




RN 497067-93-3 CAPLUS

CN Methanesulfonamide, N-[5-[2-(11-ethyl-2-fluoro-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-1-naphthalenyl]-1-naphthalenyl- (9CI) (CA INDEX NAME)




RN 497067-94-4 CAPLUS

CN Methanesulfonamide, N-[5-[2-(11-ethyl-2-fluoro-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-1-naphthalenyl]-1,1,1-trifluoro- (9CI) (CA INDEX NAME)




RN 497067-95-5 CAPLUS

CN Methanesulfonamide, N-[5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-1-naphthalenyl]- (9CI)
(CA INDEX NAME)




RN 497067-96-6 CAPLUS

CN 1-Naphthalenesulfonamide, 5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 497067-97-7 CAPLUS

CN Acetamide, N-[[5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-1-naphthalenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 497067-98-8 CAPLUS

CN Butanoic acid, 4-[[5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-1-naphthalenyl]amino]-4-oxo- (9CI) (CA INDEX NAME)




RN 497067-99-9 CAPLUS

CN Butanoic acid, 4-[[5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-1-naphthalenyl]amino]-2,2-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 497068-00-5 CAPLUS

CN Glycine, N-[[5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-1-naphthalenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 497068-01-6 CAPLUS

CN 1-Naphthaleneacetic acid, 5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 497068-02-7 CAPLUS

CN 1-Naphthalenecarboxylic acid, 5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 497068-03-8 CAPLUS

CN 1-Naphthalenepropanoic acid, 5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 497068-04-9 CAPLUS

CN 1-Naphthaleneacetamide, 5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 497068-05-0 CAPLUS

CN 2-Propenoic acid, 3-[5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-1-naphthalenyl]- (9CI)
(CA INDEX NAME)




RN 497068-06-1 CAPLUS

CN 2-Propenoic acid, 3-[5-[2-(11-ethyl-2-fluoro-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-1-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 497068-07-2 CAPLUS

CN 2-Propenoic acid, 3-[5-[2-(11-ethyl-2-fluoro-6,11-dihydro-4-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-1-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 497068-08-3 CAPLUS

CN 2-Propenoic acid, 3-[5-[2-(2-chloro-11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-1-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 497068-09-4 CAPLUS

CN 2-Propenoic acid, 3-[5-[2-(11-ethyl-6,11-dihydro-2,5-dimethyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-1-naphthalenyl]- (9CI)
(CA INDEX NAME)




RN 497068-10-7 CAPLUS

CN 2-Propenoic acid, 3-[5-[2-(11-ethyl-6,11-dihydro-2,4-dimethyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-1-naphthalenyl]- (9CI)
(CA INDEX NAME)




RN 497068-11-8 CAPLUS

CN 2-Propenoic acid, 3-[5-[2-(11-ethyl-6,11-dihydro-4-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-1-naphthalenyl]- (9CI)
(CA INDEX NAME)




RN 497068-12-9 CAPLUS

CN 1-Naphthalenepropanoic acid, 5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-, hydrazide (9CI) (CA INDEX NAME)




RN 497068-13-0 CAPLUS

CN 1-Naphthalenepropanoic acid, 5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-α-methyl- (9CI)
(CA INDEX NAME)




RN 497068-14-1 CAPLUS

CN 2-Propenoic acid, 3-[5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-1-naphthalenyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 497068-15-2 CAPLUS

CN 2-Naphthalenecarboxylic acid, 6-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 497068-16-3 CAPLUS

CN 2-Naphthalenecarboxylic acid, 6-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-, hydrazide (9CI) (CA INDEX NAME)




RN 497068-17-4 CAPLUS

CN Alanine, N-[[6-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-2-naphthalenyl]carbonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 497068-18-5 CAPLUS

CN 2-Naphthaleneacetic acid, 6-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 497068-19-6 CAPLUS

CN 2-Naphthaleneacetic acid, 6-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-, hydrazide (9CI) (CA INDEX NAME)




RN 497068-20-9 CAPLUS

CN 2-Naphthaleneacetic acid, 6-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-5-methyl- (9CI) (CA INDEX NAME)




RN 497068-21-0 CAPLUS

CN 1H-Indene-4-carboxylic acid, 7-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 497068-22-1 CAPLUS

CN 1H-Indene-4-carboxylic acid, 7-[2-(2-chloro-11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 497068-23-2 CAPLUS

CN 1-Naphthalenecarboxylic acid, 4-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)




RN 497068-24-3 CAPLUS

CN 1-Naphthalenecarboxylic acid, 4-[2-(2-chloro-11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)




RN 497068-25-4 CAPLUS

CN 1-Naphthalenecarboxylic acid, 4-[2-(11-ethyl-2-fluoro-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)




RN 497068-26-5 CAPLUS

CN 1-Naphthalenecarboxylic acid, 4-[2-(11-ethyl-6,11-dihydro-2,5-dimethyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)




RN 497068-27-6 CAPLUS

CN 1-Naphthalenecarboxylic acid, 4-[2-(11-ethyl-6,11-dihydro-2-methoxy-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)




RN 497068-28-7 CAPLUS

CN 1-Naphthaleneacetic acid, 4-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)




RN 497068-29-8 CAPLUS

CN 1-Naphthaleneacetic acid, 4-[2-(2-chloro-11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)




RN 497068-30-1 CAPLUS

CN 1-Naphthaleneacetic acid, 4-[2-(11-ethyl-2-fluoro-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)




RN 497068-31-2 CAPLUS

CN 1-Naphthalenepropanoic acid, 4-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)




RN 497068-32-3 CAPLUS

CN 1-Naphthalenepropanoic acid, 4-[2-(2-chloro-11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)




RN 497068-33-4 CAPLUS

CN 1(2H)-Quinolineacetic acid, 5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 497068-34-5 CAPLUS

CN 1(2H)-Quinolinepropanoic acid, 5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-3,4-dihydro-β-oxo- (9CI) (CA INDEX NAME)




RN 497068-35-6 CAPLUS

CN 2,8(1H)-Isoquinolinedicarboxylic acid, 5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-3,4-dihydro-, 2-methyl ester (9CI) (CA INDEX NAME)




RN 497068-36-7 CAPLUS

CN 2,8(1H)-Isoquinolinedicarboxylic acid, 5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-3,4-dihydro-, 2-(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 497068-37-8 CAPLUS

CN 8-Isoquinolinecarboxylic acid, 2-acetyl-5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 497068-38-9 CAPLUS

CN 8-Isoquinolinecarboxylic acid, 5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-1,2,3,4-tetrahydro-2-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 497068-39-0 CAPLUS

CN 8-Isoquinolinecarboxylic acid, 2-[(ethylamino)carbonyl]-5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 497068-40-3 CAPLUS

CN 8-Isoquinolinecarboxylic acid, 2-[(dimethylamino)carbonyl]-5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 497068-41-4 CAPLUS

CN 8-Isoquinolinecarboxylic acid, 2-[(dimethylamino)sulfonyl]-5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)



RN 497068-90-3 CAPLUS

CN 1-Naphthalenecarboxylic acid, 4-[2-(2-chloro-11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]- (9CI)
(CA INDEX NAME)




IT 497068-77-6 497068-81-2

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of dipyridodiazepinones as reverse transcriptase inhibitors)


RN 497068-77-6 CAPLUS

CN 1-Naphthaleneacetic acid, 4-[2-(2-chloro-11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-, methyl ester
(9CI) (CA INDEX NAME)



RN 497068-81-2 CAPLUS

CN 2-Naphthalenecarboxylic acid, 6-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-, methyl ester (9CI)
(CA INDEX NAME)




IT 497068-42-5P 497068-48-1P 497068-51-6P
497068-52-7P 497068-64-1P 497068-66-3P
497068-72-1P 497068-74-3P 497068-75-4P
497068-82-3P 497068-86-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of dipyridodiazepinones as reverse transcriptase inhibitors)


RN 497068-42-5 CAPLUS

CN 1-Naphthalenecarboxaldehyde, 4-[2-(11-ethyl-2-fluoro-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]- (9CI) (CA
INDEX NAME)




RN 497068-48-1 CAPLUS

CN 1-Naphthaleneacetic acid, 4-[2-(11-ethyl-2-fluoro-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 497068-51-6 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[4-[2-(11-ethyl-2-fluoro-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-1-naphthalenyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 497068-52-7 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[(5-amino-1-naphthalenyl)oxy]ethyl]-11-ethyl-2-fluoro-5,11-dihydro-5-methyl- (9CI)
(CA INDEX NAME)




RN 497068-64-1 CAPLUS

CN 1H-Indene-4-carboxylic acid, 7-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-2,3-dihydro-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 497068-66-3 CAPLUS

CN 1-Naphthalenecarboxylic acid, 4-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-5,6,7,8-tetrahydro-, ethyl ester (9CI) (CA INDEX NAME)




RN 497068-72-1 CAPLUS

CN 2,8(1H)-Isoquinolinedicarboxylic acid, 5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-3,4-dihydro-, 2-(1,1-dimethylethyl) 8-ethyl ester (9CI) (CA INDEX NAME)




RN 497068-74-3 CAPLUS

CN 1(2H)-Quinolinecarboxylic acid, 5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 497068-75-4 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-ethyl-5,11-dihydro-5-methyl-8-[2-[(1,2,3,4-tetrahydro-5-quinolinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 497068-82-3 CAPLUS

CN Alanine, N-[[6-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-2-naphthalenyl]carbonyl]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 497068-86-7 CAPLUS

CN 1(2H)-Quinolinepropanoic acid, 5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-3,4-dihydro-β-oxo-, methyl ester (9CI) (CA INDEX NAME)




RE.CNT 4


THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2002:754386 CAPLUS Full-text
 DN 137:263074
 TI Preparation of dipyrindodiazepinones as reverse transcriptase inhibitors
 IN Ogilvie, William W.; Deziel, Robert; Naud, Julie; O'Meara, Jeffrey
 PA Boehringer Ingelheim (Canada) Ltd., Can.
 SO PCT Int. Appl., 97 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002076982	A2	20021003	WO 2002-CA385	20020321
	WO 2002076982	A3	20021212		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2003069226	A1	20030410	US 2002-96779	20020313
	US 6716836	B2	20040406		
	CA 2441996	AA	20021003	CA 2002-2441996	20020321
	EP 1373267	A2	20040102	EP 2002-716563	20020321
	EP 1373267	B1	20050202		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	JP 2004523590	T2	20040805	JP 2002-576240	20020321
	AT 288434	E	20050215	AT 2002-716563	20020321
	PT 1373267	T	20050531	PT 2002-716563	20020321
	ES 2236500	T3	20050716	ES 2002-2716563	20020321
PRAI	US 2001-278044P	P	20010322		
	WO 2002-CA385	W	20020321		
OS	MARPAT 137:263074				
GI					



I



II

AB Title compds. [I; R = Z2Z3R5; R1 = H, halo, alkyl, alkoxy, etc.; R2,R3 = H or Me; R4 = H, (cyclo)alkyl, etc.; R5 = e.g., benzoisothiazolyl group II (R8 = bond); R6,R7 = H, Me, etc.; R6R7 = O; 1 of Z,Z1 = SO2 and the other = (un)substituted NH; Z2 = alkylene; Z3 = O or S] were prepared Thus, I (R = CH2CH2OR5; R1 = R2 = H, R3 = Me, R4 = Et) (III; R5 = H) was etherified by II (R6 = R7 = H, Z = NR9, Z1 = SO2) (IV; R8 = OH, R9 = CO2Et) (preparation given) to give, after deprotection, III (R5 = IV, R8 = bond, R9 = H). Data for biol. activity of I were given.


IT 463337-98-6P 463338-00-3P 463338-02-5P
 463338-08-1P 463338-11-6P 463338-14-9P
 463338-17-2P 463338-20-7P 463338-23-0P
 463338-26-3P 463338-28-5P 463338-30-9P

463338-33-2P 463338-36-5P 463338-39-8P
 463338-42-3P 463338-45-6P 463338-48-9P
 463338-51-4P 463338-54-7P 463338-57-0P
 463338-61-6P 463338-64-9P 463338-67-2P
 463338-70-7P 463338-72-9P 463338-75-2P
 463338-86-5P 463338-88-7P 463338-90-1P
 463338-92-3P 463338-94-5P 463338-97-8P
 463339-00-6P 463339-03-9P 463339-06-2P
 463339-09-5P 463339-12-0P 463339-23-3P
 463339-26-6P 463339-29-9P 463339-32-4P
 463339-35-7P 463339-38-0P 463339-42-6P
 463339-46-0P 463339-50-6P 463339-54-0P
 463339-58-4P 463339-62-0P 463339-65-3P
 463339-68-6P 463339-71-1P 463339-74-4P
 463339-78-8P 463339-82-4P 463339-86-8P
 463339-89-1P 463339-92-6P 463339-95-9P
 463339-98-2P 463340-01-4P 463340-04-7P
 463340-07-0P 463340-10-5P 463340-13-8P
 463340-16-1P 463340-19-4P 463340-22-9P
 463340-25-2P 463340-28-5P 463340-31-0P
 463340-34-3P 463340-36-5P 463340-39-8P
 463340-42-3P 463340-45-6P 463340-48-9P
 463340-51-4P 463340-54-7P 463340-57-0P
 463340-60-5P 463340-63-8P 463340-66-1P
 463340-69-4P 463340-72-9P 463340-75-2P
 463340-78-5P 463340-81-0P 463340-84-3P
 463340-87-6P 463340-90-1P 463340-93-4P
 463340-96-7P 463340-99-0P 463341-02-8P
 463341-05-1P 463341-08-4P 463341-11-9P
 463341-14-2P 463341-17-5P 463341-20-0P
 463341-23-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses) (preparation of dipyridodiazepinones as reverse transcriptase
 inhibitors)

RN 463337-98-6 CAPLUS


CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[(1,3-dihydro-2,2-
 dioxido-2,1-benzisothiazol-4-yl)oxy]ethyl]-11-ethyl-5,11-dihydro-5-methyl-
 (9CI) (CA INDEX NAME)



RN 463338-00-3 CAPLUS


CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[(1,3-dihydro-2,2-
 dioxido-2,1-benzisothiazol-4-yl)oxy]ethyl]-11-ethyl-2-fluoro-5,11-dihydro-

5-methyl- (9CI) (CA INDEX NAME)




RN 463338-02-5 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[[[(1,3-dihydro-2,2-dioxido-2,1-benzisothiazol-4-yl)oxy)methyl]-11-ethyl-2-fluoro-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 463338-08-1 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-cyclopropyl-8-[2-[(1,3-dihydro-2,2-dioxido-2,1-benzisothiazol-4-yl)oxy]ethyl]-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 463338-11-6 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-cyclopropyl-8-[2-[(1,3-dihydro-2,2-dioxido-2,1-benzisothiazol-4-yl)oxy]ethyl]-2-fluoro-5,11-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 463338-14-9 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[[[(1,3-dihydro-1-methyl-2,2-dioxido-2,1-benzisothiazol-4-yl)oxy]methyl]-11-ethyl-2-fluoro-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 463338-17-2 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[[[(1,3-dihydro-1,3-dimethyl-2,2-dioxido-2,1-benzisothiazol-4-yl)oxy)methyl]-11-ethyl-2-fluoro-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 463338-20-7 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[(1,3-dihydro-2,2-dioxido-2,1-benzisothiazol-4-yl)oxy]ethyl]-11-ethyl-5,11-dihydro-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 463338-23-0 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[(1,3-dihydro-2,2-dioxido-2,1-benzisothiazol-4-yl)oxy]ethyl]-11-ethyl-2-fluoro-5,11-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 463338-26-3 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[(1,3-dihydro-1-methyl-2,2-dioxido-2,1-benzisothiazol-4-yl)oxy]ethyl]-11-ethyl-2-fluoro-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 463338-28-5 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[(1,3-dihydro-1-methyl-2,2-dioxido-2,1-benzisothiazol-4-yl)oxy]ethyl]-11-ethyl-2-fluoro-5,11-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 463338-30-9 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[(1,3-dihydro-2,2-dioxido-2,1-benzisothiazol-4-yl)oxy]ethyl]-11-ethyl-5,11-dihydro-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 463338-33-2 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-ethyl-8-[2-[(1-ethyl-1,3-dihydro-2,2-dioxido-2,1-benzisothiazol-4-yl)oxy]ethyl]-5,11-dihydro-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 463338-36-5 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-cyclopropyl-8-[2-[(1,3-dihydro-1-methyl-2,2-dioxido-2,1-benzisothiazol-4-yl)oxy]ethyl]-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 463338-39-8 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[(1,3-dihydro-1,7-dimethyl-2,2-dioxido-2,1-benzisothiazol-4-yl)oxy]ethyl]-11-ethyl-5,11-dihydro-2-methyl- (9CI) (CA INDEX NAME)




RN 463338-42-3 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-cyclopropyl-8-[2-[(1,3-dihydro-1-methyl-2,2-dioxido-2,1-benzisothiazol-4-yl)oxy]ethyl]-2-fluoro-5,11-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 463338-45-6 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-cyclopropyl-8-[2-[(1,3-dihydro-1-methyl-2,2-dioxido-2,1-benzisothiazol-4-yl)oxy]ethyl]-2-fluoro-5,11-dihydro-4,5-dimethyl- (9CI) (CA INDEX NAME)




RN 463338-48-9 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[(1,3-dihydro-2,2-dioxido-2,1-benzisothiazol-4-yl)oxy]ethyl]-11-ethyl-5,11-dihydro-4-methyl-(9CI) (CA INDEX NAME)




RN 463338-51-4 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[[1-(cyclopropylmethyl)-1,3-dihydro-2,2-dioxido-2,1-benzisothiazol-4-yl]oxy]ethyl]-11-ethyl-5,11-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 463338-54-7 CAPLUS

CN 2,1-Benzisothiazole-1(3H)-carboxylic acid, 4-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-, ethyl ester, 2,2-dioxide (9CI) (CA INDEX NAME)



RN 463338-57-0 CAPLUS


CN 2,1-Benzisothiazole-1(3H)-acetic acid, 4-[2-(11-ethyl-5,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-, 2,2-dioxide (9CI) (CA INDEX NAME)




RN 463338-61-6 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[[1,3-dihydro-2,2-dioxido-1-(4-pyridinylmethyl)-2,1-benzisothiazol-4-yl]oxy]ethyl]-11-ethyl-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 463338-64-9 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[[1,3-dihydro-1-(2-hydroxyethyl)-2,2-dioxido-2,1-benzisothiazol-4-yl]oxy]ethyl]-11-ethyl-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 463338-67-2 CAPLUS


CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[[1,3-dihydro-2,2-dioxido-1-[(1-oxido-4-pyridinyl)methyl]-2,1-benzisothiazol-4-yl]oxy]ethyl]-11-ethyl-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)



PAGE 1-A





RN 463338-70-7 CAPLUS
 CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[[1,3-dihydro-2,2-dioxido-1-(3-pyridinylmethyl)-2,1-benzisothiazol-4-yl]oxy]ethyl]-11-ethyl-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)




Et

RN 463338-72-9 CAPLUS
 CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[[1,3-dihydro-2,2-dioxido-1-[(1-oxido-3-pyridinyl)methyl]-2,1-benzisothiazol-4-yl]oxy]ethyl]-11-ethyl-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 463338-75-2 CAPLUS
 CN 2,1-Benzisothiazole-1(3H)-acetamide, 4-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-N-hydroxy-, 2,2-dioxide (9CI) (CA INDEX NAME)




RN 463338-86-5 CAPLUS

CN 2,1-Benzisothiazole-1(3H)-acetamide, 4-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-N-hydroxy-N-methyl-, 2,2-dioxide (9CI) (CA INDEX NAME)





RN 463338-88-7 CAPLUS

CN 2,1-Benzisothiazole-1(3H)-butanoic acid, 4-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-, ethyl ester, 2,2-dioxide (9CI) (CA INDEX NAME)





RN 463338-90-1 CAPLUS


CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[[[1,3-dihydro-2,2-dioxido-1-[(1-oxido-4-pyridinyl)methyl]-2,1-benzisothiazol-4-yl]oxy]ethyl]-11-ethyl-5,11-dihydro-4,5-dimethyl- (9CI) (CA INDEX NAME)



RN 463338-92-3 CAPLUS
 CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[[1,3-dihydro-2,2-dioxido-1-[(1-oxido-3-pyridinyl)methyl]-2,1-benzisothiazol-4-yl]oxy]ethyl]-11-ethyl-5,11-dihydro-4,5-dimethyl- (9CI) (CA INDEX NAME)




RN 463338-94-5 CAPLUS
 CN 2,1-Benzisothiazole-1(3H)-propanoic acid, 4-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]- α -methyl-, 2,2-dioxide (9CI) (CA INDEX NAME)




RN 463338-97-8 CAPLUS
 CN 2,1-Benzisothiazole-1(3H)-acetamide, N-cyclopropyl-4-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-, 2,2-dioxide (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 463339-00-6 CAPLUS
 CN 2,1-Benzisothiazole-1(3H)-acetamide, N-ethyl-4-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-, 2,2-dioxide (9CI) (CA INDEX NAME)




RN 463339-03-9 CAPLUS

CN 2,1-Benzisothiazole-1(3H)-acetamide, 4-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-N-(1-oxido-4-pyridinyl)-, 2,2-dioxide (9CI) (CA INDEX NAME)



PAGE 1-A





RN 463339-06-2 CAPLUS


CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[[1,3-dihydro-2,2-dioxido-1-[2-(4-pyridinyloxy)ethyl]-2,1-benzisothiazol-4-yl]oxy]ethyl]-11-ethyl-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 463339-09-5 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[[1,3-dihydro-2,2-dioxido-1-[2-[(1-oxido-4-pyridinyl)oxy]ethyl]-2,1-benzisothiazol-4-yl]oxy]ethyl]-11-ethyl-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)



PAGE 1-A





PAGE 2-A





RN 463339-12-0 CAPLUS
CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-cyclopropyl-8-[2-[[1,3-dihydro-2,2-dioxido-1-[(1-oxido-4-pyridinyl)methyl]-2,1-benzisothiazol-4-yl]oxy]ethyl]-5,11-dihydro-4-methyl- (9CI) (CA INDEX NAME)





RN 463339-23-3 CAPLUS
 CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[[1,3-dihydro-2,2-dioxido-1-[(1-oxido-4-pyridinyl)methyl]-2,1-benzisothiazol-4-yl]oxy]ethyl]-11-ethyl-2-fluoro-5,11-dihydro-4-methyl- (9CI) (CA INDEX NAME)





RN 463339-26-6 CAPLUS
 CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 2-chloro-8-[2-[[1,3-dihydro-2,2-dioxido-1-[(1-oxido-4-pyridinyl)methyl]-2,1-benzisothiazol-4-yl]oxy]ethyl]-11-ethyl-5,11-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 463339-29-9 CAPLUS
 CN 2,1-Benzisothiazole-1(3H)-carboxamide, 4-[2-(2-chloro-11-ethyl-5,11-dihydro-4-methyl-6-oxo-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-2,2-dioxido-N-(1-oxido-4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 463339-32-4 CAPLUS
 CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[[[1,3-dihydro-2,2-dioxido-1-[(1-oxido-4-pyridinyl)methyl]-2,1-benzisothiazol-4-yl]oxy)methyl]-11-ethyl-2-fluoro-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 463339-35-7 CAPLUS
 CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[(2,3-dihydro-1,1-dioxido-1,2-benzisothiazol-4-yl)oxy]ethyl]-11-ethyl-5,11-dihydro-5-methyl-
 (9CI) (CA INDEX NAME)




RN 463339-38-0 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[(2,3-dihydro-1,1-dioxido-1,2-benzisothiazol-4-yl)oxy]ethyl]-11-ethyl-2-fluoro-5,11-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 463339-42-6 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[(2,3-dihydro-3,3-dimethyl-1,1-dioxido-1,2-benzisothiazol-4-yl)oxy]ethyl]-11-ethyl-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 463339-46-0 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-cyclopropyl-8-[2-[(2,3-dihydro-3,3-dimethyl-1,1-dioxido-1,2-benzisothiazol-4-yl)oxy]ethyl]-5,11-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 463339-50-6 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[(2,3-dihydro-1,1-dioxido-1,2-benzisothiazol-5-yl)oxy]ethyl]-11-ethyl-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 463339-54-0 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[(2,3-dihydro-2-methyl-1,1-dioxido-1,2-benzisothiazol-5-yl)oxy]ethyl]-11-ethyl-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 463339-58-4 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[(2,3-dihydro-3,3-dimethyl-1,1-dioxido-1,2-benzisothiazol-5-yl)oxy]ethyl]-11-ethyl-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 463339-62-0 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[(2,3-dihydro-2,3,3-trimethyl-1,1-dioxido-1,2-benzisothiazol-5-yl)oxy]ethyl]-11-ethyl-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 463339-65-3 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[(2,3-dihydro-1,1-dioxido-1,2-benzisothiazol-5-yl)oxy]ethyl]-11-ethyl-2-fluoro-5,11-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 463339-68-6 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[(2,3-dihydro-3,3-dimethyl-1,1-dioxido-1,2-benzisothiazol-5-yl)oxy]ethyl]-11-ethyl-5,11-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 463339-71-1 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[(2,3-dihydro-3,3-dimethyl-1,1-dioxido-1,2-benzisothiazol-5-yl)oxy]ethyl]-11-ethyl-2-fluoro-5,11-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 463339-74-4 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[(1,3-dihydro-2,2-dioxido-2,1-benzisothiazol-5-yl)oxy]ethyl]-11-ethyl-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 463339-78-8 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[[(1,3-dihydro-2,2-dioxido-2,1-benzisothiazol-5-yl)oxy]methyl]-11-ethyl-2-fluoro-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 463339-82-4 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[(1,3-dihydro-3,3-dimethyl-2,2-dioxido-2,1-benzisothiazol-5-yl)oxy]ethyl]-11-ethyl-2-fluoro-5,11-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 463339-86-8 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[(2,3-dihydro-1,1-dioxido-3-oxo-1,2-benzisothiazol-5-yl)oxy]ethyl]-11-ethyl-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 463339-89-1 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[(2,3-dihydro-2-methyl-1,1-dioxido-3-oxo-1,2-benzisothiazol-5-yl)oxy]ethyl]-11-ethyl-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 463339-92-6 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[(3,4-dihydro-2,2-dioxido-1H-1,2-benzothiazin-5-yl)oxy]ethyl]-11-ethyl-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)





RN 463339-95-9 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[(3,4-dihydro-2,2-dioxido-1H-2,1-benzothiazin-5-yl)oxy]ethyl]-11-ethyl-2-fluoro-5,11-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 463339-98-2 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[[3,4-dihydro-1-[2-(4-morpholinyl)ethyl]-2,2-dioxido-1H-1,2-benzothiazin-5-yl]oxy]ethyl]-11-ethyl-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 463340-01-4 CAPLUS
 CN 1H-2,1-Benzothiazine-1-acetamide, 5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-3,4-dihydro-, 2,2-dioxide (9CI) (CA INDEX NAME)




RN 463340-04-7 CAPLUS
 CN 1H-2,1-Benzothiazine, 5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-3,4-dihydro-1-(4-morpholinylcarbonyl)-, 2,2-dioxide (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 463340-07-0 CAPLUS
 CN 1H-2,1-Benzothiazine, 5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-3,4-dihydro-1-(1-pyrrolidinylcarbonyl)-, 2,2-dioxide (9CI) (CA INDEX NAME)



Et


RN 463340-10-5 CAPLUS
 CN 1H-2,1-Benzothiazine-1-carboxamide, N,N-diethyl-5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-3,4-dihydro-, 2,2-dioxide (9CI) (CA INDEX NAME)




RN 463340-13-8 CAPLUS
 CN 1H-2,1-Benzothiazine, 5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-3,4-dihydro-1-[(4-methyl-

1-piperazinyl)carbonyl}-, 2,2-dioxide (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 463340-16-1 CAPLUS



CN 1H-2,1-Benzothiazine-1-carboxamide, 5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-3,4-dihydro-N-methoxy-N-methyl-, 2,2-dioxide (9CI) (CA INDEX NAME)



RN 463340-19-4 CAPLUS
 CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[[1-[2-(diethylamino)ethyl]-3,4-dihydro-2,2-dioxido-1H-1,2-benzothiazin-5-yl]oxy]ethyl]-11-ethyl-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 463340-22-9 CAPLUS
 CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[[3,4-dihydro-2,2-dioxido-1-(4-pyridinylmethyl)-1H-1,2-benzothiazin-5-yl]oxy]ethyl]-11-ethyl-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)



RN 463340-25-2 CAPLUS


CN 1H-2,1-Benzothiazine-1-acetic acid, 5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-3,4-dihydro-, 2,2-dioxide (9CI) (CA INDEX NAME)




RN 463340-28-5 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[[3,4-dihydro-1-[(2-methyl-4-thiazolyl)methyl]-2,2-dioxido-1H-1,2-benzothiazin-5-yl]oxy]ethyl]-11-ethyl-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 463340-31-0 CAPLUS

CN Pyrrolidine, 1-[[5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-3,4-dihydro-2,2-dioxido-1H-2,1-benzothiazin-1-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 463340-34-3 CAPLUS
 CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[[3,4-dihydro-1-(2-hydroxyethyl)-2,2-dioxido-1H-1,2-benzothiazin-5-yl]oxy]ethyl]-11-ethyl-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)



RN 463340-36-5 CAPLUS


CN 1H-2,1-Benzothiazine-1-acetic acid, 5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-3,4-dihydro-, methyl ester, 2,2-dioxide (9CI) (CA INDEX NAME)




RN 463340-39-8 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[[3,4-dihydro-2,2-dioxido-1-[(1-oxido-4-pyridinyl)methyl]-1H-1,2-benzothiazin-5-yl]oxy]ethyl]-11-ethyl-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 463340-42-3 CAPLUS

CN 1H-2,1-Benzothiazine-1-butanoic acid, 5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-3,4-dihydro-, 2,2-dioxide (9CI) (CA INDEX NAME)




RN 463340-45-6 CAPLUS
 CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[[3,4-dihydro-2,2-dioxido-1-[2-oxo-2-(1H-tetrazol-5-yl)ethyl]-1H-1,2-benzothiazin-5-yl]oxy]ethyl]-11-ethyl-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 463340-48-9 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[[3,4-dihydro-1-
[(methylsulfonyl)methyl]-2,2-dioxido-1H-1,2-benzothiazin-5-yl]oxy]ethyl]-
11-ethyl-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 463340-51-4 CAPLUS

CN 1H-2,1-Benzothiazine-1-butanoic acid, 5-[2-(11-ethyl-6,11-dihydro-5-methyl-
6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-3,4-dihydro-,
ethyl ester, 2,2-dioxide (9CI) (CA INDEX NAME)



RN 463340-54-7 CAPLUS


CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[[3,4-dihydro-2,2-
dioxido-1-(3-pyridinylmethyl)-1H-1,2-benzothiazin-5-yl]oxy]ethyl]-11-ethyl-
5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)



Et

RN 463340-57-0 CAPLUS


CN 1H-2,1-Benzothiazine-1-propanesulfonamide, 5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-3,4-dihydro-, 2,2-dioxide (9CI) (CA INDEX NAME)



RN 463340-60-5 CAPLUS

CN 1H-2,1-Benzothiazine-1-acetamide, 5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-


oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-3,4-dihydro-N-(methylsulfonyl)-, 2,2-dioxide (9CI) (CA INDEX NAME)




RN 463340-63-8 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[[3,4-dihydro-2,2-dioxido-1-[(1-oxido-3-pyridinyl)methyl]-1H-1,2-benzothiazin-5-yl]oxy]ethyl]-11-ethyl-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 463340-66-1 CAPLUS

CN 1H-2,1-Benzothiazine-1-ethanesulfonic acid, 5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-3,4-dihydro-, 2,2-dioxide (9CI) (CA INDEX NAME)




RN 463340-69-4 CAPLUS

CN 1H-2,1-Benzothiazine-1-butanoic acid, 5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-3,4-dihydro- α,α -dimethyl-, 2,2-dioxide (9CI) (CA INDEX NAME)




RN 463340-72-9 CAPLUS

CN 1H-2,1-Benzothiazine-1-butanamide, 5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-3,4-dihydro-, 2,2-dioxide (9CI) (CA INDEX NAME)




RN 463340-75-2 CAPLUS

CN 1H-2,1-Benzothiazine-1-butanoic acid, 5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-3,4-dihydro-, hydrazide, 2,2-dioxide (9CI) (CA INDEX NAME)



RN 463340-78-5 CAPLUS


CN Alanine, N-[[5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-3,4-dihydro-2,2-dioxo-1H-2,1-benzothiazin-1-yl]acetyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 463340-81-0 CAPLUS

CN Cyclopropanecarboxylic acid, 1-[[[5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-3,4-dihydro-2,2-dioxido-1H-2,1-benzothiazin-1-yl]acetyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 463340-84-3 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[[1-[2-((aminocarbonyl)oxy)ethyl]-3,4-dihydro-2,2-dioxido-1H-2,1-benzothiazin-5-yl]oxy]ethyl]-11-ethyl-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 463340-87-6 CAPLUS

CN 1H-2,1-Benzothiazine-1-butanoic acid, 5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-3,4-dihydro-, 2-(2,2,2-trifluoroethyl)hydrazide, 2,2-dioxide (9CI) (CA INDEX NAME)



RN 463340-90-1 CAPLUS


CN Alanine, N-[[5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-3,4-dihydro-2,2-dioxido-1H-2,1-benzothiazin-1-yl]acetyl]-2-methyl-, hydrazide (9CI) (CA INDEX NAME)



RN 463340-93-4 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[[3,4-dihydro-1-(1H-imidazol-2-ylmethyl)-2,2-dioxido-1H-2,1-benzothiazin-5-yl]oxy]ethyl]-11-ethyl-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

Et

RN 463340-96-7 CAPLUS


CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[(3,4-dihydro-1,1-

dioxido-2H-1,2-benzothiazin-5-yl)oxy]ethyl]-11-ethyl-5,11-dihydro-5-methyl-
(9CI) (CA INDEX NAME)




RN 463340-99-0 CAPLUS

CN 2H-1,2-Benzothiazine-2-butanoic acid, 5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-3,4-dihydro-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 463341-02-8 CAPLUS

CN 2H-1,2-Benzothiazine-2-butanoic acid, 5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-3,4-dihydro-, hydrazide, 2,2-dioxide (9CI) (CA INDEX NAME)




RN 463341-05-1 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-ethyl-5,11-dihydro-5-methyl-8-[2-[(1-methyl-2,2-dioxido-1H-2,1-benzothiazin-5-yl)oxy]ethyl]-(9CI) (CA INDEX NAME)




RN 463341-08-4 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-ethyl-5,11-dihydro-4-methyl-8-[2-[(1-methyl-2,2-dioxido-1H-2,1-benzothiazin-5-yl)oxy]ethyl]-(9CI) (CA INDEX NAME)




RN 463341-11-9 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-ethyl-5,11-dihydro-8-[2-[(1-methyl-2,2-dioxido-1H-2,1-benzothiazin-5-yl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 463341-14-2 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 5,11-diethyl-5,11-dihydro-8-[2-[(1-methyl-2,2-dioxido-1H-2,1-benzothiazin-5-yl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 463341-17-5 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-ethyl-8-[2-[(1-ethyl-2,2-dioxido-1H-2,1-benzothiazin-5-yl)oxy]ethyl]-5,11-dihydro-5-methyl- (9CI)
(CA INDEX NAME)




RN 463341-20-0 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[(2,2-dioxido-1H-2,1-benzothiazin-5-yl)oxy]ethyl]-11-ethyl-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)



RN 463341-23-3 CAPLUS

CN 1H-2,1-Benzothiazine-1-butanoic acid, 5-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-, 2,2-dioxide (9CI) (CA INDEX NAME)




IT 463341-72-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of dipyridodiazepinones as reverse transcriptase inhibitors)

RN 463341-72-2 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 8-[2-[[2,3-dihydro-1,1-dioxido-3-oxo-2-(phenylmethyl)-1,2-benzisothiazol-5-yl]oxy]ethyl]-11-ethyl-5,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)



L10 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2001:923799 CAPLUS Full-text

DN 136:37632

TI Preparation of non-nucleoside reverse transcriptase inhibitors

IN Simoneau, Bruno

PA Boehringer Ingelheim (Canada) Ltd., Can.

SO PCT Int. Appl., 76 pp.



CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2001096338	A1	20011220	WO 2001-CA890	20010614
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	BR 2001002377	A	20020219	BR 2001-2377	20010612
	US 2002028807	A1	20020307	US 2001-879447	20010612
	US 6420359	B2	20020716		
	CA 2411766	AA	20011220	CA 2001-2411766	20010614
	EP 1294720	A1	20030326	EP 2001-949124	20010614
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004502787	T2	20040129	JP 2002-510480	20010614
	EE 200200690	A	20040615	EE 2002-690	20010614
	NZ 523549	A	20040827	NZ 2001-523549	20010614
	ZA 2002009807	A	20031016	ZA 2002-9807	20021203
	BG 107348	A	20040630	BG 2002-107348	20021203
	NO 2002005844	A	20021205	NO 2002-5844	20021205
	HK 1057558	A1	20050408	HK 2004-100468	20040121
PRAI	US 2000-212329P	P	20000616		
	US 2000-256638P	P	20001218		
	WO 2001-CA890	W	20010614		
OS	MARPAT 136:37632				
GI					



AB Compds. of formula I [R2 = H, F, Cl, (C1-4) alkyl, (C3-4) cycloalkyl, CF3; R4 = H, Me; R5 = H, Me, Et; R4 and R5 are not both Me, and if R4 is Me then R5 cannot be Et; R11 = Et, cyclopropyl, Pr, iso-Pr, isobutyl; Q = 4- or 5-quinolinyl or their 1-oxides] are prepared as inhibitors of HIV reverse transcriptase, wild-type and several mutant strains. Thus, II was prepared in several steps from 2-chloro-3-nitropyridine, ethylamine, 5-bromo-2-chloro-3-pyridinecarbonyl chloride and 4-hydroxyquinoline. II was shown to inhibit wild-type and mutant strains of reverse transcriptase in assays.

IT 380378-78-9P 380378-79-0P 380378-80-3P


380378-83-6P 380378-85-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of dipyridodiazepinone derivs. as reverse transcriptase inhibitors)


RN 380378-78-9 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-ethyl-2-fluoro-5,11-dihydro-5-methyl-8-[2-[(1-oxido-5-quinolinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 380378-79-0 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 2-chloro-11-ethyl-5,11-dihydro-4-methyl-8-[2-[(1-oxido-5-quinolinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 380378-80-3 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 2-chloro-11-ethyl-5,11-dihydro-5-methyl-8-[2-[(1-oxido-5-quinolinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 380378-83-6 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-ethyl-2-fluoro-5,11-dihydro-4-methyl-8-[2-[(1-oxido-5-quinolinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 380378-85-8 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 2-chloro-11-ethyl-5,11-dihydro-4-methyl-8-[2-(5-quinolinyloxy)ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1998:450899 CAPLUS Full-text
 DN 129:170109
 TI Novel Nonnucleoside Inhibitors of HIV-1 Reverse Transcriptase. 8.
 8-Aryloxymethyl- and 8-Arylthiomethyldipyridodiazepinones
 AU Cywin, Charles L.; Klunder, Janice M.; Hoermann, MaryAnn; Brickwood,
 Janice R.; David, Eva; Grob, Peter M.; Schwartz, Racheline; Pauletti,
 Daniel; Barringer, Kevin J.; Shih, Cheng-Kon; Sorge, Christopher L.;
 Erickson, David A.; Joseph, David P.; Hattox, Susan E.
 CS Research and Development Center, Boehringer Ingelheim Pharmaceuticals
 Inc., Ridgefield, CT, 06877, USA
 SO Journal of Medicinal Chemistry (1998), 41(16), 2972-2984
 CODEN: JMCMAR; ISSN: 0022-2623
 PB American Chemical Society
 DT Journal
 LA English
 GI



III

AB Nevirapine is the first human immunodeficiency virus type 1 (HIV-1) nonnucleoside reverse transcriptase (RT) inhibitor to reach regulatory approval. As a result of a second generation program around the tricyclic core system of nevirapine, 2-chloro-5,11-dihydro-11-ethyl-5-methyl-8-(2-(pyridin-4-yl)ethyl)-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one (I) and 2-chloro-5,11-dihydro-11-ethyl-5-methyl-8-phenylethyl-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one (II) were identified as broad spectrum HIV-1 RT inhibitors. A detailed examination of replacing either of the methylenes of the 8-Et linker of I or II is presented. It was found that 8-aryloxymethyl and 8-arylthiomethyl are the preferred pattern of substitution for potency against RT. The most potent compds. were further evaluated against a panel of clin. significant mutant RT enzymes (K103N, V106A, G190A, P236L) and in cytotoxicity and in vitro metabolism assays. The most potent compound was 2-chloro-8-phenylthiomethyl analog III which displayed sub-100 nM activity against all HIV-1 RT enzymes tested.


IT 189392-46-9P 189392-48-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(8-aryloxymethyl- and 8-arylthiomethyldipyridodiazepinones as non-nucleoside inhibitors of HIV-1 reverse transcriptase)


RN 189392-46-9 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 2-chloro-11-ethyl-5,11-dihydro-8-[(1H-indol-4-yloxy)methyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 189392-48-1 CAPLUS


CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 2-chloro-11-ethyl-5,11-dihydro-8-[(1H-indol-5-yloxy)methyl]-5-methyl- (9CI) (CA INDEX NAME)



RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1998:31142 CAPLUS Full-text
 DN 128:114968
 TI Preparation of 8-aralkyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepines for treatment of HIV-1 infection.
 IN Cywin, Charles L.; Hoermann, Maryann; Klunder, Janice M.
 PA Boehringer Ingelheim Pharmaceuticals, Inc., USA
 SO U.S., 39 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5705499	A	19980106	US 1996-710996	19960925
PRAI	US 1996-710996		19960925		
OS	MARPAT 128:114968				
GI					




AB Title compds. [I; A = chain of 1-3 atoms, cyclopropylene, oxiranylene; Ar = (substituted) 5-6 membered (hetero)aryl; R1 = H, alkyl, fluoroalkyl, alkenylmethyl, alkynylmethyl, (substituted) aryl, arylmethylalkanoyl, thioalkanoyl, alkylsulfonyl, etc.; Z = O, S, NCN, alkoximino; R2 = H, alkyl, fluoroalkyl, cycloalkyl, oxetanyl, thietanyl, tetrahydrofuryl, alkenylmethyl, alkynylmethyl, alkoxyalkyl, alkylthioalkyl, alkanoyl, cyano, cyanoalkyl, hydroxyalkyl, acyloxyalkyl, etc.; R3 = H, alkyl, alkenyl, alkynyl, trihalomethyl, hydroxyalkyl, alkoxyalkyl, alkylthioalkyl, halo; R4 = H, Me, halo; R5 = H; R3R4 or R4R5 = cycloalkyl; with provisos], were prepared Thus, 2-chloro-5,11-dihydro-11-ethyl-5-methyl- 8-[2-(pyrid-4-yloxy)ethyl]-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one (preparation given) showed an IC50 = 0.03 μ M in the syncytia assay using HIV-1 in CD4+ T-cells.

IT **189392-46-9P 189392-48-1P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of aralkyldihydrodipyridodiazepines for treatment of HIV-1 infection)


RN 189392-46-9 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 2-chloro-11-ethyl-5,11-dihydro-8-[(1H-indol-4-yloxy)methyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 189392-48-1 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 2-chloro-11-ethyl-5,11-dihydro-8-[(1H-indol-5-yloxy)methyl]-5-methyl- (9CI) (CA INDEX NAME)



L10 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1997:350585 CAPLUS Full-text

DN 126:317394

TI 8-Arylalkyl- and 8-arylheteroalkyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepines and their use in the prevention or treatment of HIV infection

IN Cywin, Charles L.; Hoermann, Maryann; Klunder, Janice M.

PA Boehringer Ingelheim Pharmaceuticals Inc., USA

SO Eur. Pat. Appl., 62 pp.



CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 767172	A1	19970409	EP 1996-115901	19961004
	EP 767172	B1	20030326		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	CA 2187146	AA	19970407	CA 1996-2187146	19961004
	JP 09188680	A2	19970722	JP 1996-264860	19961004
	AT 235495	E	20030415	AT 1996-115901	19961004
	PT 767172	T	20030829	PT 1996-115901	19961004
	ES 2191075	T3	20030901	ES 1996-115901	19961004
PRAI	US 1995-4806P	P	19951006		
	US 1995-8695P	P	19951215		
OS	MARPAT 126:317394				
GI					



AB The invention relates to novel 8-arylalkyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepines of general formula I [A = (un)substituted connecting chain of 1-3 atoms, 1,2-cyclopropanediyl, oxiranediyl; Ar = certain (un)substituted (un)fused heteroarom. groups; Z = :O, :S, :NCN, :NOR8; R1 = H, alkyl, fluoroalkyl, alkenylmethyl, (hetero)aryl, alkanoyl, etc.; R2 = H, alkyl, fluoroalkyl, oxetanyl, tetrahydrofuranyl, cyano, oxazolyl, etc.; R3 = alkyl, alkenyl, alkynyl, trihalomethyl, hydroxyalkyl, halo, etc.; R4 = H, Me, halo, and R5 = H; or R3 = R5 = H, and R4 = Me or halo; or R3 = R4 = H, and R5 = alkyl, cycloalkyl, trihalomethyl, hydroxyalkyl, aryloxymethyl, etc.; or R3R4 or R4R5 forms cycloalkyl and R5 or R3 = H; or R3 = R4 = R5 = H; R6 = R7 = H;

R8 = alkyl] and their pharmaceutically acceptable salts. The compds. are inhibitors of HIV-1 reverse transcriptase (RT), and are thus useful in the prevention or treatment of HIV infection. For instance, 2-chloro-5,11-dihydro-11-ethyl- 8-iodo-5-methyl-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one was coupled with 4-vinylpyridine in the presence of Pd(PPh₃)₂Cl₂ and Et₃N, and the alkenylated product was reduced by aqueous Na hypophosphite in the presence of Pd black, to give title compound II. In an assay for inhibition of recombinant RT in vitro, II gave 95% inhibition at 1 mM. I were also active in a syncytial assay in human T-cells, and exhibited both high enzymic specificity for HIV-1 RT, and relatively low cytotoxicity in an MTT assay.


IT 189392-46-9P 189392-48-1P

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of dipyridodiazepines as HIV-1 reverse transcriptase inhibitors)


RN 189392-46-9 CAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 2-chloro-11-ethyl-5,11-dihydro-8-[(1H-indol-4-yloxy)methyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 189392-48-1 CAPLUS


CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 2-chloro-11-ethyl-5,11-dihydro-8-[(1H-indol-5-yloxy)methyl]-5-methyl- (9CI) (CA INDEX NAME)



=> d 12; d 16; d his; log y

L2 HAS NO ANSWERS

L1 STR




Structure attributes must be viewed using STN Express query preparation.

L2 QUE ABB=ON PLU=ON L1

L6 HAS NO ANSWERS

L5 STR



Structure attributes must be viewed using STN Express query preparation.

L6 QUE ABB=ON PLU=ON L5

(FILE 'HOME' ENTERED AT 17:46:44 ON 16 NOV 2005)

FILE 'REGISTRY' ENTERED AT 17:46:52 ON 16 NOV 2005

L1 STRUCTURE UPLOADED

L2 QUE L1

L3 20 S L2

L4 517 S L2 FUL

L5 STRUCTURE UPLOADED

L6 QUE L5

L7 9 S L6 SAM SUB=L4

L8 259 S L6 FUL SUB=L4

L9 258 S L4 NOT L8

FILE 'CAPLUS' ENTERED AT 17:49:00 ON 16 NOV 2005

L10 8 S L9

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

40.42

241.30

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-5.84

-5.84

STN INTERNATIONAL LOGOFF AT 17:49:57 ON 16 NOV 2005